Clinical trials: Schizophrenia Disorder
Depression, Schizophrenia
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00034801
- Testing
- olanzapine, ziprasidone
- Where
- 30 sites in United States
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A review of the amount of drug in your blood over time.
- Trial name
- NCT02186769
- Testing
- Risperdal® Consta®, LY03004
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet
The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks and vice-versa.
- Trial name
- PREFERENCE (NCT00324051)
- Testing
- olanzapine therapy
- Where
- 8 sites in Brazil, Romania and 1 more
- Volunteers
- 284 people
- Sponsor
- Eli Lilly and Company
Psychotic Disorders
Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder
This is a 24-week, observational, prospective study to evaluate the effectiveness of improving cognitive function of aripiprazole in treating adolescents and young adults with psychotic disorder in Taiwan.
- Trial name
- NCT00541502
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Schizophrenia
IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)
To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia
- Trial name
- NCT00136994
- Testing
- Ziprasidone
- Where
- 34 sites in Italy
- Volunteers
- 160 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Schizophrenia Study In Adults
A Placebo Controlled Study For Patients With Schizophrenia
- Trial name
- NCT00049946
- Testing
- talnetant, risperidone
- Where
- 31 sites in United States
- Volunteers
- 231 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00549718
- Testing
- Lurasidone HCl
- Where
- 48 sites in United States, France and 5 more
- Volunteers
- 489 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting.
- Trial name
- PLEASURE (NCT01160679)
- Where
- 12 sites in South Korea
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Schizophrenia
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
- Trial name
- NCT00036127
- Testing
- aripiprazole
- Where
- 16 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cognitive Impairment, Schizophrenia
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia
- Trial name
- NCT04822883
- Testing
- RL-007
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Recognify Life Sciences
Schizophrenia
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia.
- Trial name
- NCT00103727
- Testing
- Talnetant, risperidone
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- GlaxoSmithKline
Tardive Dyskinesia
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00917293
- Testing
- Pyridoxal 5'-Phosphate
- Where
- 4 sites in Canada, India
- Volunteers
- 53 people
- Sponsor
- Medicure
Schizophrenia
A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia
The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia.
- Trial name
- NCT01606228
- Testing
- Paliperidone ER
- Volunteers
- 188 people
- Sponsor
- Janssen Pharmaceutica
Schizophrenia
A Study of Lurasidone HCl in Subjects With Schizophrenia
The study evaluates the effectiveness and safety of Lurasidone in subjects with schizophrenia over a period of 6 weeks.
- Trial name
- NCT03393026
- Testing
- Lurasidone
- Where
- 2 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- Standard Chem. & Pharm. Co., Ltd.
Healthy
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00620568
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to…
- Trial name
- NCT03397134
- Testing
- Roluperidone 32 mg, Roluperidone 64 mg
- Where
- 39 sites in United States, Bulgaria and 2 more
- Volunteers
- 515 people
- Sponsor
- Minerva Neurosciences
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar® Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.
- Trial name
- NCT07722728
- Testing
- 30 mg B2227, 70 mg B2227, 150 mg B2227
- Volunteers
- 84 people
- Sponsor
- Bostal Drug Delivery Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.